Ronald Martell, Jasper Therapeutics CEO
Jasper scraps pivotal plans but adds a new indication as more biotechs revise pipelines
A suite of biopharmas disclosed cuts to their pipelines this week as the industry gets a sweeping update of drugs in the works as part …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
